N/A N=50 Bariatric Surgery for Morbid Obesity
Obesity · Morbid Obesity
Primary: Size of Adipocytes — 73.4; 99.0; 103.0 µm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=38 Targeting Obesity to Optimize Health in Cardiac Rehab (TOPCARE)
Obesity · Weight Loss · CHD - Coronary Heart Disease
Primary: Feasibility - Number of Enrolled Participants — 38 Participants
N/A N=314 Reducing Cardiometabolic Risk and Promoting Functional Health in Older Adults With Obesity and Prediabetes
Obesity · PreDiabetes · Aging
Primary: Change in Bodyweight — -7.4; -6.1 percentage of bodyweight change — p=0.196
Phase 3 N=2,487 Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions
Obesity · Type 2 Diabetes
Primary: Percent Weight Loss From Baseline to Week 56 — 1.24; 7.81; 9.84 percent weight loss — p=<0.0001
N/A N=42 Teaching Obesity Treatment Options to Adult Learners Trial
Obesity · Patient Education · Weight Loss
Primary: Recruitment — 42 Participants
N/A N=47 Healthy Bodies, Healthy Kids
Child Mental Disorders · Obesity · Metabolic Syndrome
Primary: DEXA-measured Adiposity — 0.76; -0.43; -2.79 kilograms — p=0.01
Phase 2 N=272 A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
Obesity · Overweight and Obesity
Primary: Percent Change From Baseline in Body Weight in LY3502970 and Placebo — -8.6; -11.2; -12.3; -12.6 Percent change — p=<0.001
N/A N=57 Insulin-sensitive Obesity: Lessons From Longitudinal Data
Insulin Sensitivity/Resistance · Obesity
Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year
N/A N=81 Effects of Different Surgical Methods to Treat Obesity
Obesity · Type 2 Diabetes · Insulin Sensitivity
Primary: Insulin Sensitivity at 2 Years — 6.7; 6.6 glucose/kg body weight/min
Phase 4 N=150 Lifestyle Modification and Liraglutide
Obesity
Primary: Percent Change in Baseline Weight — -6.1; -11.5; -11.8 percent change
N/A N=281 Maternal-Offspring Metabolics:Family Intervention Trial
Pregnancy · Weight Gain
Primary: Gestational Weight Gain (GWG) — 12; 10 kg — p=0.01
N/A N=80 Effects of Obesity Treatments on Food Preferences and Metabolism
Obesity · Type 2 Diabetes Mellitus
Primary: Change in Energy Intake From Baseline — 500; 310; 482; 5 kcal
N/A N=88 Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes
Type 2 Diabetes Mellitus · Obesity
Primary: Fasting Plasma Glucose <126 mg/dL and HbA1c < 6.5% at Three Years of Follow-up. — 13; 5; 42; 0 % of patients — p=0.60
Phase 4 N=4,730 A Toolbox Approach to Obesity Treatment in Primary Care
Obesity
Primary: Percentage of Participants Who Achieved >5% Weight Loss at 12 Months — 34.5; 15.7 percentage of participants — p=<0.001
Phase 4 N=236 Cervical Ripening for Obese Women: A Randomized, Comparative Effectiveness Trial
Obesity · Labor Induction · Cesarean Delivery
Primary: Number of Participants With a Need for Cesarean Delivery — 51; 53 Participants
Phase 2 N=125 PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction
Healthy · Obese
Primary: Resting Energy Expenditure After 12 Weeks of Drug Therapy (kcal/Day) — 1267; 1268 kcal/day
N/A N=102 Metformin in Overweight Type 2 Diabetes Mellitus
Obesity · Type 2 Diabetes Mellitus
Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05
Phase 1 N=22 PED NEONAT 20-000599 Fetal Body Composition
IUGR · Gestational Diabetes · Pregnancy Related
Primary: Maternal Visceral Adipose Tissue Volume — 97593; 169626; 96787 mm3
N/A N=105 FoodRx for Obesity Treatment
Obesity · Food Insecurity
Primary: Percent Change in Total Body Weight at 24 Weeks (BWL+VOUCHER and BWL+HOME vs BWL-Alone) — -2.7; -3.0 Percent initial weight loss
Phase 2 N=30 Topiramate in Adolescents With Severe Obesity
Obesity, Morbid · Obesity · Weight Loss
Primary: Percent Change From Baseline in Body Mass Index at 28-Weeks — -2.74; -0.85 % change BMI
N/A N=271 Weight Discrimination and Poor Cardiovascular Health
Obesity
Primary: Negative Affect — 1.43; 1.29 score on a scale — p=.007
Phase 2 N=65 Qsymia as an Adjunct to Surgical Therapy in the Superobese
Obesity · Metabolic Surgery · Weight Loss
Primary: Proportion of Patients Who do Not Meet the Criteria to Move Forward With Roux en Y Gastric Bypass (RYGB) — 8; 19 Participants
N/A N=129 Weight Loss Physical Disabilities
Physical Disability
Primary: Weight Change in kg From Baseline to 6-months — -6.23; -8.16 kg
Phase 3 N=193 Individualized Obesity Pharmacotherapy
Obesity
Primary: Change in Total Body Weight — -7.7; -6.5 percent change
Phase 3 N=261 Obese Hypertension Study (0954-315)
Hypertension
Primary: Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 — -12.1; -6.8 mm Hg
N/A N=684 INtervention Study In overweiGHT Patients With COPD
Pulmonary Disease, Chronic Obstructive · Obesity · Weight Loss
Primary: Six Minute Walk Test — 1071.0; 1005.9 feet — p=.02
N/A N=16 Acute Exercise Effects in Obese Pregnancy
Pregnancy Complications · Obesity · Pre-Eclampsia
Primary: Oral Glucose Insulin Sensitivity (OGIS) Index — 405.0; 426.0; 418.9 uU/mL
Phase 2 N=49 Oxidative Stress in Asthma
Asthma · Obesity
Primary: Percentage of Neutrophils in Peripheral Blood — 57.3; 55.4 percentage of neutrophils — p=0.53
N/A N=264 Preventing Excessive Gestational Weight Gain in Obese Women
Obesity
Primary: Weight Gain Per Week of Observation — 0.39; 0.33 kg/wk
N/A N=3,169 MOVE OUT: A Partnership With Veterans Groups to Enhance Weight Management in the Veterans Health Administration (VHA)
Obesity · Overweight · Hypertension
Primary: Change in Weight (From Baseline) — -0.71; -0.31; -1.64; -1.06 Pounds — p=0.4937